Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653445
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00653965
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2340
- Registration Number
- NCT00654225
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4444
- Registration Number
- NCT00654173
OLE Study to Evaluate Safety / Efficacy of ZD4522
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3500
- Registration Number
- NCT00654303
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653588
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00653744
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 87
- Registration Number
- NCT00651378
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00651144
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 668
- Registration Number
- NCT00631189
- Locations
- 🇫🇷
Research Site, Yffiniac, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath